Aktienanalyse zu Atossa Therapeutics Inc (ATOS)ATOSAtossa Therapeutics Inc

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Atossa Therapeutics Inc is not a good buy right now due to its current price of $2.1568, which is significantly below its 52-week high of $14.85, indicating a steep decline of 82.84% over the past year. Furthermore, the RSI is at 37.449, suggesting the stock is nearing oversold territory but has not yet shown signs of a reversal. The forward P/E ratio is 7.0423, which may seem attractive, but the company is experiencing substantial losses with a net income of -$9,589,000 in Q1 2026 and a gross profit of $0 in Q4 2024. The main risk is the company's ongoing financial struggles, as evidenced by a current ratio of 4.92, which, while still above 1, shows declining liquidity compared to previous quarters.

1 analysts cover ATOS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.33.